Hainan Shuangcheng Pharmaceut (002693) - Total Assets
Based on the latest financial reports, Hainan Shuangcheng Pharmaceut (002693) holds total assets worth CN¥816.14 Million CNY (≈ $119.43 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how liquid is Hainan Shuangcheng Pharmaceut's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Hainan Shuangcheng Pharmaceut - Total Assets Trend (2009–2025)
This chart illustrates how Hainan Shuangcheng Pharmaceut's total assets have evolved over time, based on quarterly financial data.
Hainan Shuangcheng Pharmaceut - Asset Composition Analysis
Current Asset Composition (December 2025)
Hainan Shuangcheng Pharmaceut's total assets of CN¥816.14 Million consist of 24.8% current assets and 75.2% non-current assets. Also see Hainan Shuangcheng Pharmaceut market cap and net worth for the company's overall valuation and market capitalisation.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.2% |
| Accounts Receivable | CN¥62.21 Million | 7.5% |
| Inventory | CN¥66.09 Million | 8.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥189.34 Million | 22.9% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Hainan Shuangcheng Pharmaceut's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Hainan Shuangcheng Pharmaceut (002693) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hainan Shuangcheng Pharmaceut's current assets represent 24.8% of total assets in 2025, a decrease from 32.5% in 2009.
- Cash Position: Cash and equivalents constituted 7.2% of total assets in 2025, down from 10.2% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 12.0% in 2009.
- Asset Diversification: The largest asset category is intangible assets at 22.9% of total assets.
Hainan Shuangcheng Pharmaceut Competitors by Total Assets
Key competitors of Hainan Shuangcheng Pharmaceut based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Krka d. d
WAR:KRK
|
Poland | zł3.04 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥35.27 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Guangdong Taienkang Pharmaceutical Co. Ltd
SHE:301263
|
China | CN¥2.47 Billion |
|
Tianjin Ringpu Bio Tech
SHE:300119
|
China | CN¥7.80 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Hainan Shuangcheng Pharmaceut - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.66 | 0.80 | 1.91 |
| Quick Ratio | 0.42 | 0.35 | 1.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-103.78 Million | CN¥-34.22 Million | CN¥77.73 Million |
Hainan Shuangcheng Pharmaceut - Advanced Valuation Insights
This section examines the relationship between Hainan Shuangcheng Pharmaceut's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.51 |
| Latest Market Cap to Assets Ratio | 0.73 |
| Asset Growth Rate (YoY) | 5.3% |
| Total Assets | CN¥825.78 Million |
| Market Capitalization | $603.79 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hainan Shuangcheng Pharmaceut's assets below their book value (0.73x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hainan Shuangcheng Pharmaceut's assets grew by 5.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hainan Shuangcheng Pharmaceut (2009–2025)
The table below shows the annual total assets of Hainan Shuangcheng Pharmaceut from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥825.78 Million ≈ $120.84 Million |
+5.35% |
| 2024-12-31 | CN¥783.87 Million ≈ $114.70 Million |
-2.41% |
| 2023-12-31 | CN¥803.25 Million ≈ $117.54 Million |
-11.83% |
| 2022-12-31 | CN¥911.02 Million ≈ $133.31 Million |
+6.61% |
| 2021-12-31 | CN¥854.56 Million ≈ $125.05 Million |
-5.85% |
| 2020-12-31 | CN¥907.68 Million ≈ $132.82 Million |
-4.55% |
| 2019-12-31 | CN¥950.98 Million ≈ $139.16 Million |
-15.11% |
| 2018-12-31 | CN¥1.12 Billion ≈ $163.93 Million |
-18.65% |
| 2017-12-31 | CN¥1.38 Billion ≈ $201.52 Million |
+18.15% |
| 2016-12-31 | CN¥1.17 Billion ≈ $170.55 Million |
-24.81% |
| 2015-12-31 | CN¥1.55 Billion ≈ $226.84 Million |
+64.29% |
| 2014-12-31 | CN¥943.54 Million ≈ $138.07 Million |
+2.89% |
| 2013-12-31 | CN¥917.04 Million ≈ $134.19 Million |
+3.43% |
| 2012-12-31 | CN¥886.65 Million ≈ $129.74 Million |
+257.44% |
| 2011-12-31 | CN¥248.06 Million ≈ $36.30 Million |
-1.85% |
| 2010-12-31 | CN¥252.73 Million ≈ $36.98 Million |
+158.28% |
| 2009-12-31 | CN¥97.85 Million ≈ $14.32 Million |
-- |
About Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical injections, solid preparations, and raw materials in China and internationally. The company offers products for oncology and immune, alimentary canal, heart and cerebral, and vessels and metabolism. It also provides Bivalirudin, Epitifibatide, and Thymalfaxin for injection; Pre… Read more